Nuvation Bio to acquire AnHeart to form global oncology company
2024-03-26
临床2期并购临床1期
Preview
来源: Pharmaceutical Technology
The acquisition is aimed at bolstering the oncology pipeline of Nuvation Bio. Credit: YanLev Alexey / Shutterstock.com.
Nuvation Bio has made a definitive agreement to acquire AnHeart Therapeutics through an all-stock transaction, in a strategic move to bolster its oncology pipeline.
The deal will transform Nuvation Bio into a late-stage international oncology company with the potential to transition into a commercial entity by the end of next year.
Post-acquisition, the former AnHeart’s shareholders will hold 33% of the merged entity. Nuvation Bio’s current stockholders will own around 67%.
Current Nuvation Bio founder, CEO and president David Hung will be at the helm of the merged business while AnHeart employees in China and the US will integrate into the Nuvation Bio team.
As the new parent company, Nuvation Bio will own AnHeart’s assets, including its intellectual property.
See Also:
Which drugs are most likely to be approved in Hospital Acquired Pneumonia (HAP)?
Preview
来源: Pharmaceutical Technology
Which drugs are most likely to be approved in Community Acquired Pneumonia?
Preview
来源: Pharmaceutical Technology
The acquisition will enhance Nuvation Bio’s portfolio with promising assets such as taletrectinib, a ROS1 [proto-oncogene 1, receptor tyrosine kinase] inhibitor currently in two pivotal Phase II studies for ROS1-positive non-small cell lung cancerROS1-positive non-small cell lung cancer.
Another asset, safusidenib, is a mutant IDH1 [the isocitrate dehydrogenase-1 gene] inhibitorisocitrate dehydrogenase-1 gene] inhibitor currently being assessed in a global Phase II study of IDH1-mutant glioma.
Nuvation Bio is committed to progressing these studies, alongside advancing trials for its pipeline candidates such as the Phase Ib studies of NUV-868 and the recently initiated Phase I/II study of NUV-1511.
Hung stated: “This transaction represents a significant milestone for our company and reflects Nuvation Bio’s continued commitment to developing therapies for patients with the most difficult-to-treat cancers.
“AnHeart’s lead asset, taletrectinib, which will become our lead asset as it completes two pivotal studies, is a differentiated, next-generation ROS1 inhibitor with a potentially best-in-class profile that may overcome the significant limitations of existing therapies. We are impressed by what the AnHeart team has done to develop this asset and intend to build on the progress made to date.”
The boards of directors of both companies have approved the deal, which is anticipated to conclude in the second quarter of 2024.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。